GeneDx (NASDAQ:WGS) Reaches New 52-Week Low Following Weak Earnings

Key Points

• Shares fell to a new 52-week low after Q1 results missed expectations — EPS of $(0.28) vs. $(0.06) consensus and revenue of $102.3M vs. ~$112–114M — and management cut full‑year revenue guidance to roughly $475–$490M.
• The company reported 34% year‑over‑year volume growth in exome and genome testing, suggesting operational traction that could support long‑term revenue if margins and cash flow improve.
• Analysts pared price targets (e.g., BTIG $170→$90, Guggenheim $100→$70) and investor risk is elevated by recent insider selling and a shareholder investigation, increasing near‑term uncertainty.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) shares hit a new 52-week low on Tuesday following a dissappointing earnings announcement. The stock traded as low as $37.80 and last traded at $37.1970, with a volume of 695043 shares trading hands. The stock had previously closed at $67.93.

The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The business had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. During the same period in the previous year, the firm posted ($0.23) EPS.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Solid operational traction — GeneDx reported 34% year-over-year volume growth in exome and genome testing, a metric that supports long‑term revenue potential if margin trends stabilize. Business Wire: Q1 Results & Outlook
• Neutral Sentiment: Company materials and the earnings call transcript are available for deeper color on drivers, cost items and management commentary — useful for investors wanting to parse forward guidance and margin assumptions. Earnings Call Transcript
• Negative Sentiment: Q1 results missed expectations: EPS of ($0.28) vs. consensus (~($0.06)) and revenue ~$102.3M vs. estimates near $112–114M; the quarter included a much larger operating and net loss and weaker cash flow, prompting negative investor reaction. Zacks: Q1 Loss & Revenue Miss QuiverQuant: Detailed Q1 Financials
• Negative Sentiment: Full‑year revenue guidance was pulled down to ~$475–$490M versus a consensus near $549M, increasing investor concern about near‑term growth and the path to profitability. Business Wire: Guidance Update
• Negative Sentiment: Analysts cut price targets: BTIG trimmed its target to $90 (from $170) and Guggenheim to $70 (from $100), both keeping buy ratings but signaling lower near‑term valuation expectations. Such cuts can pressure sentiment and limit near‑term upside. Benzinga: Analyst Target Cuts TickerReport: BTIG Note
• Negative Sentiment: Legal risk: a shareholder law firm (Johnson Fistel) announced an investigation into potential claims regarding executive conduct and investor losses, which can create uncertainty and potential litigation costs. GlobeNewswire: Investigation Notice
• Negative Sentiment: Insider selling: multiple insider sales have been reported recently (including CEO and other officers), which investors may view as a negative signal about near‑term confidence. QuiverQuant: Insider Transactions American Banking News: CFO Sale

Analysts Set New Price Targets

Several brokerages have commented on WGS. BTIG Research lowered their price target on GeneDx from $170.00 to $90.00 and set a "buy" rating on the stock in a report on Tuesday. Piper Sandler reaffirmed an "overweight" rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a research note on Wednesday, January 21st. Canaccord Genuity Group set a $75.00 target price on shares of GeneDx in a research report on Tuesday. Finally, Wall Street Zen cut shares of GeneDx from a "buy" rating to a "hold" rating in a report on Sunday, February 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $98.33.

Insiders Place Their Bets

In other news, COO Bryan Dechairo sold 5,961 shares of the firm's stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total value of $510,857.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 392 shares of the business's stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48. Following the transaction, the chief financial officer directly owned 34,942 shares in the company, valued at $2,277,868.98. This trade represents a 1.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 109,989 shares of company stock valued at $7,888,023 over the last ninety days. 29.60% of the stock is owned by insiders.

Institutional Investors Weigh In On GeneDx

Several hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its holdings in shares of GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company's stock worth $158,738,000 after purchasing an additional 52,322 shares in the last quarter. Vanguard Group Inc. lifted its position in GeneDx by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company's stock worth $154,650,000 after purchasing an additional 18,647 shares during the period. Franklin Resources Inc. boosted its stake in GeneDx by 60.4% during the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company's stock worth $142,154,000 after buying an additional 411,607 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company's stock valued at $132,435,000 after buying an additional 474,167 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of GeneDx by 59.2% during the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company's stock worth $102,288,000 after acquiring an additional 292,394 shares during the period. Institutional investors own 61.72% of the company's stock.

GeneDx Stock Performance

The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -48.21 and a beta of 2.06. The firm's 50-day moving average price is $71.45 and its two-hundred day moving average price is $107.17. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.